Argenx Launches $750 Million Global Offering
By Sabela Ojea
Argenx said Monday that it is offering $750 million of ordinary shares.
The biotechnology company said the offering will be comprised of ordinary shares represented by American Depository Shares in the U.S. and other countries outside the European Economic Area, and a simultaneous private placement of ordinary shares in the European Economic Area and the U.K.
The company's shares ended the trading session on Monday up 28% at $484.43.
Argenx's offering comes a month after the company said it received Food and Drug Administration approval for its Vyvgart Hytrulo injection to treat certain adult patients with generalized myasthenia gravis, a chronic autoimmune, neuromuscular disease that can weaken skeletal muscles.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
July 17, 2023 16:43 ET (20:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month